A double-masked comparison of carteolol and timolol in ocular hypertension.
We performed a double-masked study in which 98 patients with ocular hypertension who had been previously treated with timolol received either timolol 0.25% or carteolol 1%, a beta-blocker with intrinsic sympathomimetic activity. The drugs were administered topically twice daily for one month after a one-week washout period. Intraocular pressure was measured at baseline and after one and four weeks of treatment. The appearance of the fundus, external eye, visual fields, tear secretion, blood pressure, and pulse were recorded. Adverse symptoms were elicited using a menu-type questionnaire and an overall judgment of therapy was recorded. Carteolol was as effective as timolol in reducing intraocular pressure. There were significantly fewer patients reporting adverse events overall (P = .019), and eye irritation specifically (P = .02), in the group treated with carteolol.
Scoville
B
B
Office of Clinical Research, Otsuka Pharmaceutical Co., Rockville, Maryland 20850.
Mueller
B
B
White
B G
BG
Krieglstein
G K
GK
D000287:Administration, Topical; D000553:Ambulatory Care; D002354:Carteolol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011412:Propanolamines / Q000627:therapeutic use*; D013999:Timolol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D009883:Ophthalmic Solutions; D011412:Propanolamines; D013999:Timolol; D002354:Carteolol